Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (168)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Differential blood-based biomarkers of subcortical and deep brain small vessel disease

    Therapeutic Advances in Neurological Disorders, Vol. 17

  3. Hypothalamic free fatty acid receptor-1 regulates whole-body energy balance

    Molecular Metabolism, Vol. 79

  4. Inflammatory bowel disease induces pathological α-synuclein aggregation in the human gut and brain

    Neuropathology and Applied Neurobiology, Vol. 50, Núm. 1

  5. Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks

    Neurology, Vol. 103, Núm. 6

  6. Ionizable nanoemulsions for RNA delivery into the central nervous system – importance of diffusivity

    Journal of Controlled Release, Vol. 372, pp. 295-303

  7. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  8. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

  9. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 760-776

  10. Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke

    International Journal of Molecular Sciences, Vol. 25, Núm. 12

  11. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

    European Archives of Psychiatry and Clinical Neuroscience

  4. Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship

    Journal of Clinical Periodontology, Vol. 50, Núm. 11, pp. 1444-1454

  5. Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner

    Nature Communications, Vol. 14, Núm. 1

  6. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  7. Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 861-871

  8. Combined cell-based therapy strategies for the treatment of Parkinson's disease: Focus on mesenchymal stromal cells

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 478-484

  9. Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders

    Brain Sciences, Vol. 13, Núm. 2